Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leiomodin-2 (LMOD2) is a muscle-specific, actin-binding protein primarily expressed in cardiac muscle, where it is essential for the elongation and regulation of thin filaments within sarcomeres. LMOD2 mediates actin nucleation and polymerization, specifically binding at the pointed ends of actin filaments to promote elongation without capping—a role crucial for achieving mature filament length. Its absence or dysfunction leads to abnormal thin filament morphology, defective sarcomere assembly, and severe reduction of contractile force, culminating in dilated cardiomyopathy or other myopathies. LMOD2 is not currently a therapeutic target, nor are there approved drugs or biomarkers targeting it, but it is mechanistically central to muscle contractility and a cause of inherited muscle diseases when mutated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leiomodin-2 (LMOD2).